Routes of Drug Administration Part 2: Physiological Considerations

What is a significant influence on the ultimate drug deposition patterns in pulmonary drug administration?

What is the average optimal particle size for deep lung drug deposition in pulmonary drug administration?

Which type of drug administration can result in both local and systemic effects depending on drug deposition?

How do pulmonary pathological conditions affect drug deposition patterns?

Which factor plays a crucial role in differentiating formulations and devices for pulmonary drug administration?

What is a key advantage of drugs absorbed from the lungs?

Why must formulations intended for parenteral administration be sterile, nonimmunogenic, and pyrogen free?

Which factor influences the rate and extent of systemic drug availability following parenteral administration?

How do intradermal and subcutaneous injections differ in terms of drug absorption?

Why might some insulin formulations slow the rate of drug release after subcutaneous administration?

What is the optimal average particle size for drug deposition in the deep lung during pulmonary drug administration?

Which factor plays a crucial role in determining the differences between formulations and devices used in pulmonary drug administration?

How can pulmonary drug administration lead to systemic effects?

What type of delivery does pulmonary drug administration involve?

How are inhaled drugs typically administered to the respiratory system?

Why is it essential for formulations intended for parenteral administration to be sterile, nonimmunogenic, and pyrogen free?

What distinguishes intradermal (ID) injections from subcutaneous (SC) injections in terms of drug administration?

Which factor contributes to the unpredictable systemic drug concentrations after subcutaneous (SC) drug administration?

Why do drugs absorbed from the lungs avoid hepatic first-pass metabolism?

How does drug absorption after intravenous (IV) administration differ from other routes?